CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 15/04/2026 BST			5-day change	1st Jan Change
180.56 ^USD	+0.70%		+6.50%	-9.48%

04-14	Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says	MT
04-14	Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $200, Maintains Overweight Rating	MT

All News

04-14	Charles River Laboratories Positioned as 'Leading' CRO as Preclinical R&D Inflection Nears, RBC Says	MT
04-14	Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $200, Maintains Overweight Rating	MT
04-14	RBC Initiates Charles River Laboratories International at Outperform With $215 Price Target	MT
04-09	Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association	BU
04-08	Baird Raises Price Target on Charles River Laboratories International to $200 From $197, Maintains Outperform Rating	MT
04-06	NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX	PR
03-31	AI-led selloff in contract research firms may be misjudging disruption risk	RE
03-12	Locus Cell Co., Ltd. And Charles River Laboratories Sign Memorandum Of Understanding For Cell And Gene Therapy Collaboration	CI
03-10	Charles River Laboratories International, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 10:00 AM
03-09	Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193	MT
03-05	Therna Biosciences, Inc. Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics	CI
03-03	Charles River Laboratories International, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM
03-02	Charles River Laboratories to Present at TD Cowen and Barclays Conferences	BU
02-25	IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE : CRL) for $155 million.	CI
02-25	GI Manager L.P. signed a definitive agreement to acquire Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc..	CI
02-25	UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating	MT
02-25	Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated	MT
02-25	Charles River raises annual profit view as it sells underperforming assets	RE
02-25	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026	CI
02-25	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30	MT
02-25	Charles River Laboratories Provides Update on Planned Divestitures	BU
02-20	Rothschild & Co Redburn Adjusts Charles River Laboratories PT to $200 From $211, Maintains Buy Rating	MT
02-20	Mizuho Securities Adjusts Charles River Laboratories Price Target to $175 From $215, Maintains Neutral Rating	MT
02-20	TD Cowen Adjusts Price Target on Charles River Laboratories International to $235 From $251, Maintains Buy Rating	MT
02-19	Jefferies Adjusts Price Target on Charles River Laboratories International to $225 From $255, Maintains Buy Rating	MT